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Somatostatin is an important modulator of neurotransmission in the central nervous sys-
tem and acts as a potent inhibitor of hormone and exocrine secretion and regulator of cell
proliferation in the periphery.These pleiotropic actions occur through interaction with ﬁve G
protein-coupled somatostatin receptor subtypes (sst1−5) that are widely expressed in the
brain and peripheral organs. The characterization of somatostatin’s effects can be inves-
tigated by pharmacological or genetic approaches using newly developed selective sst
agonists and antagonists and mice lacking speciﬁc sst subtypes. Recent evidence points
toward a divergent action of somatostatin in the brain and in the periphery to regulate cir-
culating levels of ghrelin, an orexigenic hormone produced by the endocrine X/A-like cells
in the rat gastric mucosa. Somatostatin interacts with the sst2 in the brain to induce an
increase in basal ghrelin plasma levels and counteracts the visceral stress-related decrease
in circulating ghrelin. By contrast, stimulation of peripheral somatostatin-sst2 signaling
results in the inhibition of basal ghrelin release and mediates the postoperative decrease
in circulating ghrelin. The peripheral sst2-mediated reduction of plasma ghrelin is likely
to involve a paracrine action of D cell-derived somatostatin acting on sst2 bearing X/A-
like ghrelin cells in the gastric mucosa. The other member of the somatostatin family,
named cortistatin, in addition to binding to sst1 also directly interacts with the ghrelin−5
receptor and therefore may simultaneously modulate ghrelin release and actions at target
sites bearing ghrelin receptors representing a link between the ghrelin and somatostatin
systems.
Keywords: X/A-like cell, somatostatin receptor subtypes, ghrelin cell, somatostatin receptor agonists and
antagonist, cortistatin
INTRODUCTION
In 1972, Guillemin’s group – while searching for additional
releasing factors in hypothalamic extracts after their identiﬁ-
cation of thyrotropin-releasing hormone (TRH) – identiﬁed a
novel negative regulator of pituitary somatotropic cells releasing
growth hormone (GH; Brazeau et al., 1973). The cyclo peptide
was named somatostatin (somatotropin release-inhibiting factor,
SRIF), in keeping with its hypophysiotropic action (Guillemin,
2011). Somatostatin was found to be expressed in two biologically
active isoforms: the tetradecapeptide somatostatin-14 (Brazeau
et al., 1973) and the amino terminally extended octacosapep-
tide somatostatin-28 generated by differential post-translational
processing from a common precursor molecule (Pradayrol et al.,
1980). Thereafter, a ﬂow of articles in rodents and humans estab-
lished the ubiquitous distribution of somatostatin in various brain
areas (Finley et al., 1981; Johansson et al., 1984; Uhl et al., 1985)
and peripheral organs including the gastrointestinal tract (Costa
et al., 1977; Walsh, 1994). This was followed by the identiﬁca-
tion and characterization of ﬁve distinct, high-afﬁnity, speciﬁc
somatostatin receptors (sst) encoded by ﬁve distinct genes (Gahete
et al., 2010a). Structurally, these receptors belong to the so-called
“superfamily” of membrane G protein-coupled (GPC) receptors.
The sst1−5 have distinct as well as overlapping patterns of distribu-
tion in the brain (Fehlmann et al., 2000; Spary et al., 2008) and gut
(Schafer and Meyerhof, 1999; Ludvigsen et al., 2004; Corleto et al.,
2006) with a prominent expression of sst2 in the gastrointestinal
tract (Sternini et al., 1997). Studies using new pharmacological
tools, namely selective sst subtype agonists and antagonists (Grace
et al., 2006; Cescato et al., 2008; Erchegyi et al., 2008, 2009; Table 1)
point toward the role of different sst1−5 in mediating the large
spectrum of somatostatin biological actions, mostly inhibitory in
nature. Multiple effects of somatostatin can also result from the
ability of sst to form both homodimers or heterodimers (sst5 with
sst1 or dopamine D2 receptor, sst2a with sst3, D2 or μ opioid
receptor subtype 1) resulting in the activation of different intra-
cellular signaling cascades (Rocheville et al., 2000; Baragli et al.,
2007; Siehler et al., 2008).
Of interest to neuroendocrinologists, somatostatin’s inhibitory
action on pituitary GH release was soon extended to a wide
range of hypophyseal hormones including prolactin, thyrotropin
(thyroid-stimulating hormone, TSH), and adrenocorticotropic
hormone (ACTH; Brown et al., 1984; Bertherat et al., 1995;
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Table 1 | Structure and receptor binding affinity of somatostatin and somatostatin receptor agonists.
Peptide Structure Receptor binding affinity (IC50, nM)a
sst1 sst2 sst3 sst4 sst5
Somatostatin-14
(Viollet et al., 1995)
Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-
Cys]-OH
0.1–1.5 1.7 1.7 1.0–1.6 0.2–2.2
Somatostatin-28
(Viollet et al., 1995)
Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-
Lys-Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-
Thr-Ser-Cys]-OH
0.1–4.7 0.4–5.2 0.2 0.3–1.1 0.05–0.19
Octreotide
(Grace et al., 2008)
H-(D)-Phe2-c[Cys3-Phe7-DTrp8-Lys9-Thr10-Cys14]-
Thr15(ol)
>1K 1.9 ± 0.3 39 ± 14 >1K 5.1 ± 1.1
ODT8-SST
(Erchegyi et al., 2008)
des-AA1,2,4,5,12,13-(DTrp8)-SST 27.0 ± 3.4 41.0 ± 8.7 13.0 ± 3.2 1.8 ± 0.7 46.0 ± 27.0
Cortistatin-17
(Fukusumi et al., 1997)
Asp-Arg-Met-Pro-cyclo-[Cys-Arg-Asn-Phe-Phe-Trp-Lys-
Thr-Phe-Ser-Ser-Cys]Lys
0.3–7.0 0.6–0.9 0.4–0.6 0.5–0.6 0.3–0.4
sst1 agonist
(Erchegyi et al., 2009)
des-AA1,4−6,10,12,13-[DTyr2,D-Agl(NMe,2naphtoyl)8,
IAmp9]-SST-Thr-NH2
0.19 ± 0.04 >1K 158.0 ± 14.0 27.0 ± 7.5 >1K
sst2 agonist
(Grace et al., 2006)
des-AA1,4−6,11−13-[DPhe2,Aph7(Cbm),DTrp8]-Cbm-
SST-Thr-NH2
>1K 7.5–20 942–1094 872–957 109–260
sst2 antagonist
(Cescato et al., 2008)
des-AA1,4−6,11−13-[pNO2-
Phe2,DCys3,Tyr7,DAph(Cbm)8]-SST-2Nal-NH2
>1K 2.6 ± 0.7 384.0 ± 97.0 >1K >1K
Receptor afﬁnities were derived from competitive radioligand displacement assays in cells stably expressing the cloned human receptor using 125I-[Leu8DTrp22Tyr25]
SST-28 (Grace et al., 2006, 2008; Cescato et al., 2008; Erchegyi et al., 2008, 2009) except for somatostatin-14 (Viollet et al., 1995), somatostatin-28 (Viollet et al., 1995),
and cortistatin (Fukusumi et al., 1997).
Shimon et al., 1997) as well as a large number of hormones
secreted fromendocrine cells of the gastrointestinal tract including
gastrin (Lloyd et al., 1997), cholecystokinin (CCK; Shiratori et al.,
1991), secretin (Shiratori et al., 1991), gastric inhibitory peptide
(GIP; Pederson et al., 1975), and neurotensin (Rokaeus, 1984),
and from the pancreas glucagon (Marco et al., 1983; Strowski
et al., 2000), insulin (Pederson et al., 1975; Marco et al., 1983;
Strowski et al., 2000), and pancreatic polypeptide (PP; Marco
et al., 1983). Studies to characterize the somatostatin receptor
subtypes established that sst2 is primarily involved and, to a
smaller extent, sst5 in the broad inhibitory effects of somato-
statin on endocrine secretion (Lloyd et al., 1997; Strowski et al.,
2000; de Heer et al., 2008). Of clinical relevance was also the
compelling evidence that the majority of neuroendocrine tumors
(NETs) expressed increased levels of sst2 leading to the develop-
ment of radiolabeled peptides and peptide receptor radionuclides
as diagnostic and therapeutic tools respectively for NETs (van
der Hoek et al., 2010; Culler et al., 2011; Giovacchini et al., 2012;
Jawiarczyk et al., 2012).
In the past decade, a signiﬁcant breakthrough came from the
identiﬁcation of a 28-amino-acid octanoylated peptide, ghrelin in
the endocrine cells of the gastric mucosa as the cognate ligand
for the GH-secretagogue receptor 1a (GHS-R1a, later renamed
ghrelin receptor, GRLN-R; Kojima et al., 2001; Davenport et al.,
2005). Ghrelin’s interaction with the GRLN-R represents a third
independent regulatory pathway controlling the pulsatile release
of pituitary GH besides the GH-releasing hormone (GHRH) and
somatostatin (Kojima et al., 2001; Malagon et al., 2003; Kineman
and Luque, 2007).
Consistent with ghrelin, being predominantly produced by the
endocrine cells of the stomach (Ariyasu et al., 2001), recent stud-
ies also documented that gastrointestinal NETs released ghrelin
(Corbetta et al., 2003; Tsolakis et al., 2004). Therefore the regula-
tion of ghrelin release by somatostatin will be of clinical relevance.
The present review focuses on recent evidence that somatostatin
signaling in the brain and the periphery exerts opposite inﬂuence
on circulating ghrelin levels. The sst receptor subtype(s) involved
and functional relevance of somatostatin-induced altered ghrelin
plasma levels in the context of orexigenic and gastric prokinetic
actions of the peptide (Kojima and Kangawa, 2005) will also be
addressed.
SOMATOSTATIN AND ITS RECEPTORS: EXPRESSION AND
MODULATION OF FEEDING BEHAVIOR AND
GASTROINTESTINAL MOTILITY
EXPRESSION OF SOMATOSTATIN AND sst
Somatostatin is expressed throughout the brain except in the
cerebellum (Finley et al., 1981; Johansson et al., 1984). Peptide
distribution has been investigated by immunohistochemistry indi-
cating the expression in the cortex, limbic system, central nucleus
of the amygdala, sensory structures, hypothalamus (including the
arcuate, ventromedial, and paraventricular nucleus), and the peri-
aqueductal central gray (Finley et al., 1981; Johansson et al., 1984;
Moga and Gray, 1985). Similarly, sst receptor mRNA expression
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is widely detected in the rat brain including the deep layers of
the cerebral cortex, bed nucleus of the stria terminalis, basolateral
amygdaloid nucleus, medial amygdaloid nucleus, paraventricu-
lar thalamic nucleus, medial preoptic nucleus, dorsomedial and
ventromedial hypothalamic nucleus, arcuate and paraventricu-
lar nucleus of the hypothalamus, substantia nigra, dorsal raphe
nucleus, granular layer of the cerebellum, locus coeruleus, nucleus
of the solitary tract, and the dorsal motor nucleus of the vagus
nerve (Fehlmann et al., 2000; Spary et al., 2008). The wide distri-
bution of the ligand along with the receptors is consistent with the
pleiotropic action of the sst signaling systems.
Somatostatin is widely expressed in the gastrointestinal tract
and the pancreas, namely in endocrine mucosal D cells scattered
within the stomach, small and large intestine, and in δ-cells of
the pancreatic islets of Langerhans (Walsh, 1994). In addition,
somatostatin is also detected in neurons of the gut enteric nervous
system within both the submucosal and myenteric plexus (Costa
et al., 1977). Similar to the ligand, sst receptor subtypes are widely
expressed in the gastrointestinal tract. In rats, mRNA expression
of sst1, sst2, sst3, and sst4 is detected in the small and large intes-
tine without any clear predominance to one segment (Schafer and
Meyerhof, 1999). The sst1 is the predominant form in gastroin-
testinal tract of mice, whereas the sst5 was almost undetectable
(Schafer and Meyerhof, 1999). In human colon, a differential
expression has been reportedwith sst2 mRNA expression on circu-
lar smooth muscle cells and sst1−3 mRNA on longitudinal muscle
layer cells (Corleto et al., 2006). Interestingly, in the pancreas pro-
tein expression of all sst1−5 receptor subtypes has been identiﬁed
on every major endocrine cell type, namely α, β, δ, and PP cells
with a differential expression pattern between species (Ludvigsen
et al., 2004).
BRAIN ACTIONS OF SOMATOSTATIN
The ﬁrst function assigned to somatostatin was the inhibition
of GH release (Brazeau et al., 1973). Now somatostatin is rec-
ognized to exert several central extrapituitary actions such as
the regulation of other pituitary endocrine hormones especially
those responsive to stress, parasympathetic and sympathetic out-
ﬂow, thermogenesis, visceral functions, and behaviors. Namely,
intracerebroventricular (icv) injection of somatostatin-28 inhib-
ited the tail suspension stress-induced rise of circulating ACTH
(Brown et al., 1984). This effect was mimicked by the stable
pan-somatostatin agonist, ODT8-SST but not by somatostatin-
14 (Brown et al., 1984). The sst2 seems to play a pivotal role in
these regulatory processes as sst2 receptor knockout mice display
an increasedACTH release compared to their wild type littermates
(Viollet et al., 2000).
With regard to the central actions of somatostatin to affect vis-
ceral functions, recent studies have focused on the gastrointestinal
tract. ODT8-SST injected intracisternally (ic) in rats accelerated
gastric emptying of a liquid non-nutrient solution. This effect
is mimicked by somatostatin-28 and the sst5 preferring agonist,
BIM-23052 but not somatostatin-14 or the agonists preferring sst1,
CH-275, sst2, DC-32-87, sst3, BIM-23056, and sst4, L-803,087
(Martinez et al., 2000) indicating a prominent role of brain sst5
activation to induce a gastroprokinetic effect. This contention
is further corroborated by the prominent mRNA expression of
sst5 in the dorsal motor nucleus of the vagus nerve (Thoss et al.,
1995). Since sst receptors are also expressed in hypothalamic brain
nuclei regulating colonic functions (Mönnikes et al., 1993; Mön-
nikes et al., 1994; Tebbe et al., 2005) including the arcuate (sst1−5;
Fehlmann et al., 2000; Schulz et al., 2000) and paraventricular
nucleus of the hypothalamus (sst2−4; Fehlmann et al., 2000; Schulz
et al., 2000) and the locus coeruleus (sst2−4; Fehlmann et al., 2000;
Schulz et al., 2000), several studies investigated whether activa-
tion of central somatostatin signaling inﬂuences colonic motor
functions. Stressing mice by short exposure to anesthesia vapor
and icv injection of vehicle robustly stimulated propulsive colonic
motor function shown by a 99% increase in fecal pellet output
(Stengel et al., 2011a). This effect was completely abolished by icv
pretreatment with ODT8-SST, somatostatin-28 and the selective
sst1 agonist, whereas sst2 or sst4 agonists or octreotide (Table 1)
had no effect. These data suggest that activation of brain sst1 can
prevent the stress-related stimulation of colonic propulsive motor
function in mice (Stengel et al., 2011a).
Central somatostatin alters food intake with a divergent action
depending on the doses used: an increase is induced by icv injec-
tion of lower (picomolar) doses and a decrease following high
(nanomolar) in rats (Feifel and Vaccarino, 1990). The stable
pan-somatostatin agonist, ODT8-SST (Erchegyi et al., 2008) icv
stimulated food intake in rats under basal as well as already stimu-
lated conditions during the dark phase with a rapid onset (during
the ﬁrst hour) and a long duration of action (lasting for 4 h; Sten-
gel et al., 2010a). ODT8-SST’s orexigenic action is sst2 mediated
as it is reproduced by icv injection of the selective peptide sst2
agonist (Stengel et al., 2010d) and blocked by the selective pep-
tide sst2 antagonist (Stengel et al., 2010a). This represents a central
action since injected intraperitoneally at a 30-fold higher dose, the
peptide did not inﬂuence food intake (Stengel et al., 2010d). The
orexigenic effect of central sst2 stimulation observed in rats has
been recently expanded to mice (Stengel et al., 2010c). A detailed
analysis of the food intake microstructure using an automated
food intake monitoring device showed that icv injection of the
sst2 agonist increased the number of meals, shortened inter-meal
intervals, and induced a higher rate of ingestion, whereas meal
sizes were not altered (Stengel et al., 2010c). Collectively, these
data indicate that brain activation of sst2 signaling pathways in
rodents induces a rapid orexigenic response by decreasing sati-
ety (number of meals), without inﬂuencing satiation indicated by
normal meal sizes (Stengel et al., 2010c). The physiological role of
brain sst2 signaling in modulating food intake is also supported
by the decrease of nocturnal food intake induced by the peptide
sst2 antagonist injected icv at the beginning of the dark phase
(Stengel et al., 2010d). In addition, hypothalamic somatostatin
shows a circadian rhythm with a peak in the early dark phase
and a nadir in the early light phase (Gardi et al., 1999). Moreover,
food restriction increases pituitary somatostatin release (Ishikawa
et al., 1997) which could increase the drive to eat under these
conditions.
PERIPHERAL ACTIONS OF SOMATOSTATIN
Contrasting to the central effects, somatostatin’s actions in the
periphery are largely inhibitory. In the stomach, somatostatin
delays emptying of the food (Smedh et al., 1999) and inhibits
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gastric acid secretion which is mediated directly by an interac-
tion with acid producing parietal cells but also via the reduced
release of histamine from ECL cells and gastrin from G cells
(Walsh, 1994). The acid-antisecretory action of somatostatin is
no longer observed in sst2 knockout mice, indicative of a primary
role of the sst2 (Piqueras et al., 2003). Similarly, in the small intes-
tine somatostatin reduces intestinal peristalsis in cats, rabbits and
rats, while stimulating the duodenal, jejunal, and ileal contrac-
tile response in dogs (Tansy et al., 1979). In line with the ﬁndings
in rodents, somatostatin increases gastrointestinal transit time in
humans (Gregersen et al., 2011). The effects on colonic motility
are likely mediated by the sst1 and sst2 based on in vitro stud-
ies using circular and longitudinal human colonic smooth muscle
cells (Corleto et al., 2006). In addition, somatostatin reduces vis-
ceral sensitivity with the sst2 playing a key role as indicated by
visceral hypersensitivity to both mechanical and chemical stim-
ulation in the jejunum of sst2 knockout mice (Rong et al., 2007).
This ﬁnding is likely to be relevant in humans as well. Patients with
irritable bowel syndrome injected subcutaneously with octreotide
display an anti-hyperalgesic response as shown by the increased
threshold of discomfort and pain using rectal barostat manome-
try compared to injection of placebo (Bradette et al., 1994; Schwetz
et al., 2004).
GHRELIN AND ITS RECEPTOR: EXPRESSION AND
PHYSIOLOGICAL OREXIGENIC AND PROKINETIC ACTIONS
EXPRESSION AND REGULATION OF GHRELIN AND GHRELIN
RECEPTOR
Ghrelin bears a unique fatty acid (n-octanoyl) residue on the
third amino acid which is essential for afﬁnity and binding to
the GRLN-R (Kojima et al., 1999; Kojima and Kangawa, 2005).
Other dietary fatty acids of medium length can also serve as a
direct source for the acylation of ghrelin (Nishi et al., 2005). The
enzyme catalyzing the acylation of ghrelin was unknown for sev-
eral years and just recently identiﬁed in mouse and human as a
member of the membrane-bound O-acyltransferases (MBOATs),
namely MBOAT4 which was subsequently renamed ghrelin-O-
acyltransferase (GOAT; Gutierrez et al., 2008; Yang et al., 2008).
GOAT mRNA and protein are prominently expressed in rodent
and human gastricmucosa in ghrelin expressing cells (Sakata et al.,
2009; Stengel et al., 2010f). In addition, GOAT protein has been
detected in rodent and human intestine, pancreatic duct, gallblad-
der, hypothalamus and pituitary gland (Gahete et al., 2010b; Lim
et al., 2011; Kang et al., 2012), rodent plasma (Stengel et al., 2010f)
and human visceral and subcutaneous adipocytes (Rodriguez
et al., 2012) leading to the speculation of additional acylation sites
of ghrelin.
Unlike ghrelin, desacyl ghrelin, which does not bear the
hydrophobic residue on the third amino acid, is the main circulat-
ing form. The acyl:desacyl ghrelin ratio is 1:3 as recently reported
using an optimized blood processing protocol to improve the yield
of acylated ghrelin in rats (Stengel et al., 2009). Although desacyl
ghrelin does not bind to and activate the GRLN-R (Kojima et al.,
1999), recent studies indicate that the peptide exerts several biolog-
ical actions to inﬂuence food intake (Stengel et al., 2010e), reduce
inﬂammatory somatic pain (Sibilia et al., 2012), muscle cachexia
producedby injury in rats (Sheriff et al., 2012) andbasal autophagy
in human visceral adipocytes (Rodriguez et al., 2012). However,
the understanding of the physiological function of this peptide is
hampered by the fact that the desacyl ghrelin receptor mediating
its effects is still to be identiﬁed.
Blood levels of ghrelin vary in relation with the meal pattern
with an increase before meals and a decrease thereafter (Cum-
mings et al., 2001; Tschöp et al., 2001a). In addition, fasting also
increases ghrelin mRNA expression (Toshinai et al., 2001; Kim
et al., 2003; Xu et al., 2009) and reduces ghrelin peptide content
in the stomach (Toshinai et al., 2001; Kim et al., 2003) indica-
tive of a stimulated production and release under conditions of
food deprivation. Ghrelin levels are not only regulated by short-
term variations in energy status associated with meal patterns but
also by long-term changes in body weight. Ghrelin plasma lev-
els are elevated under conditions of reduced body weight such
as anorexia nervosa or tumor cachexia and reduced in obesity
(Tschöp et al., 2000, 2001b; Cummings et al., 2002). Similar to
the ligand, the ghrelin acylating enzyme, GOAT is regulated by
the metabolic status with an increased GOAT mRNA and protein
expression in rodent gastric mucosa, hypothalamus, and pitu-
itary following a 12- or 24-h fast (Gonzalez et al., 2008; Gahete
et al., 2010b; Stengel et al., 2010f). Under conditions of obesity
induced by high fat diet or leptin deﬁciency in ob/ob mice, a
down-regulationof GOATmRNAoccurred in themouse pituitary,
unlike the stomach or hypothalamus (Gahete et al., 2010b), while
patients with obesity-associated type 2 diabetes showed higher lev-
els of GOAT in visceral adipose tissue (Rodriguez et al., 2012). This
indicates a tissue speciﬁc regulation of GOAT under conditions of
obesity.
OREXIGENIC AND PROKINETIC EFFECTS OF GHRELIN
Ghrelin is well established to stimulate food intake in line with its
regulation by changes in energy status in many species including
humans (Wren et al., 2000; Tang-Christensen et al., 2004; Druce
et al., 2005). It is so far the only known peripherally produced and
centrally acting orexigenic peptide, contrasting with the numer-
ous anorexigenic peptides in the gut (Suzuki et al., 2011). Ghrelin’s
action is blocked by pharmacological or genetic approaches using
GRLN-R antagonists (Salome et al., 2009) and GRLN-R knockout
mice (Sun et al., 2004; Zigman et al., 2005) indicating a key role of
ghrelin-GRLN-R interaction inmediating the orexigenic response.
The food intake stimulatory action can result from ghrelin cross-
ing the blood–brain barrier and binding to GRLN-R expressed
on food intake regulatory brain nuclei (Banks et al., 2002; Pan
et al., 2006) or acting directly on vagal afferents which also bear
the ghrelin receptor (Date et al., 2002; Sakata et al., 2003). The
respective role of these pathways under nutritional changes is still
to be delineated. In addition to the stimulation of food intake,
ghrelin is also involved in the regulation of body weight inducing
an increase of body weight following chronic infusion of the pep-
tide. This occurs through combined actions of stimulating appetite
along with increasing fat storage and reducing lipid mobilization
(Tschöp et al., 2000; Strassburg et al., 2008; Davies et al., 2009).
Further corroborating these ﬁndings, ghrelin and GRLN-R dou-
ble knockoutmice display an increased energy expenditure leading
to a reduction of body weight (Pﬂuger et al., 2008) which, how-
ever, could not be reproduced with a single genetic deletion of
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either ghrelin (Sun et al., 2003; Pﬂuger et al., 2008) or the GRLN-
R (Pﬂuger et al., 2008). These differential phenotypes may reﬂect
the functional relevance of the high constitutive activity of the
GRLN-R (Damian et al., 2012) and also give rise to the specula-
tion that additional ligands for the receptor may exist (Deghenghi
et al., 2001a).
DIFFERENTIAL MODULATION OF GH RELEASE BY GHRELIN
AND SOMATOSTATIN
Ghrelin exerts endocrine actions opposite to somatostatin by
stimulating anterior pituitary release of GH (Kojima et al., 1999;
Yamazaki et al., 2002; Kojima and Kangawa, 2011), prolactin,
and ACTH (Lanfranco et al., 2010). Somatostatin’s GH inhibitory
effect is mediated by the sst2 (Briard et al., 1997), sst5 (Saveanu
et al., 2001) and also sst1 (Kreienkamp et al., 1999). The GH releas-
ing effect of ghrelin is blunted by intravenous (iv) infusion of
somatostatin in healthy volunteers (Di Vito et al., 2002) and was
completely blocked in pig pituitary cells in vitro (Malagon et al.,
2003). The GH releasing action of ghrelin is likely to not only
result from inhibiting somatostatin release (Feng et al., 2011) but
also from direct activation of GH release (Veldhuis et al., 2006).
In addition, ghrelin and somatostatin antagonistically interact on
hypothalamic arcuate cells to regulate the release of GHRH with
an activation of these neurons following ghrelin and a reduction
after application of somatostatin in vitro (Mori et al., 2010).
ACTIVATION OF BRAIN sst2 SIGNALING INCREASES BASAL
AND PREVENTS VISCERAL STRESS-INDUCED SUPPRESSION
OF CIRCULATING GHRELIN
Based on the established centrally sst2-mediated orexigenic action
of somatostatin (Stengel et al., 2010a,d), we further investigated
whether changes in circulating ghrelin may play a role. We found
that the pan-somatostatin peptide, ODT8-SST (Table 1) injected
icv increased basal plasma acyl ghrelin levels in ad libitum fed
rats (Stengel et al., 2010a). However, the rise was observed at 3 h
postinjection and therefore unlikely to underlie the initial increase
in food intake response to central ODT8-SST which occurred
within the ﬁrst hour. However, it may contribute to the sustained
signiﬁcant increase in cumulative food intake still maintained at
4 h after icv injection of ODT8-SST (Stengel et al., 2010a). Other
studies showed that activation of brain sst2 receptor prevents the
decline in circulating ghrelin induced by visceral stress. Abdom-
inal surgery reproducibly decreased the fasting plasma levels of
acyl and desacyl ghrelin with a rapid onset and long lasting effect
in rats (Stengel et al., 2010b, 2011b,c). Such a response was com-
pletely prevented by the ic injection of ODT8-SST as monitored
50 min postsurgery at a time where the peptide induces a 31 and
46% rise in fasting circulating acyl and desacyl ghrelin, respec-
tively in sham animals (Stengel et al., 2011b). In addition, the sst2
selective peptide agonist injected ic also prevented the postopera-
tive decline in plasma levels of acyl ghrelin, whereas sst1 and sst4
agonists (Table 1) did not when tested under the same conditions
(Stengel et al., 2011b).
Of interest was the demonstration that ic ODT8-SST or sst2
agonist in addition to preventing the decline in acyl ghrelin
induced by abdominal surgery also blunted the postoperative
suppression of food intake (Stengel et al., 2011b). However, the
observed prevention of declining circulating ghrelin levels is not
the main factor for the restoration of the orexigenic response
postsurgically. The peripheral blockade of the GRLN-R using
the GRLN-R antagonist ([D-Lys3]-GHRP-6) injected intraperi-
toneally did not modify the food intake stimulating effect of ic
ODT8-SST (Stengel et al., 2011b). ODT8-SST injected icv also
restored gastric emptying inhibited by abdominal surgery to lev-
els observed under basal conditions, an effect mimicked by the
sst5 but not the sst1, sst2, and sst4 agonists in rats (Stengel et al.,
2011b). Similar to the effect on food intake, this action was not
mediated by acyl ghrelin as the intraperitoneal injection of the
GRLN-R antagonist did not inﬂuence the gastroprokinetic action
of ODT8-SST postsurgery (Stengel et al., 2011b).
Taken together, these data indicate that the central activation of
sst2 increases basal or prevents the surgical inhibitionof circulating
levels of ghrelin and food intake while activation of sst5 restores
postoperative gastric ileus in rats. It also points to a differential
role of brain sst subtypes 2 and 5 in preventing the stress-related
suppression of ghrelin release/food intake and gastric emptying,
respectively. In addition, the restoration of suppressed circulat-
ing acyl ghrelin levels after surgery does not play a major role as
underlying mechanisms through which ODT8-SST injected into
the brain exerts its prokinetic and orexigenic effects. Other stud-
ies showed that activation of sst2 and sst5 receptors in the brain
inhibits stimulated CRF release in the hypothalamus and acute
stress-relatedCRFmediatedACTHrelease (Brownet al.,1984; Tiz-
abi and Calogero, 1992; Saegusa et al., 2011; Tringali et al., 2012).
Brain CRF acting on CRF receptors is involved in the stress-related
decrease in feeding behavior, ghrelin secretion, and gastric empty-
ing (Hotta et al., 1999; Sekino et al., 2004; Taché and Bonaz, 2007;
Yakabi et al., 2011). Therefore, it may be speculated that central
activation of sst2 and/or sst5 dampens hypothalamic CRF acti-
vated by abdominal surgery (Wang et al., 2011) which may have a
bearing with preventing the reduction in feeding, gastric empty-
ing, and circulating ghrelin induced by abdominal surgery (Stengel
et al., 2011b).
ACTIVATION OF PERIPHERAL sst2 SIGNALING INHIBITS
CIRCULATING GHRELIN
In contrast to the rise in circulating ghrelin induced by central
administration of somatostatin agonists, convergent in vivo and
in vitro rodent studies established that somatostatin or the sta-
ble agonists octreotide and SOM230 act peripherally through the
sst2 to reduce ghrelin release (Seoane et al., 2007; Iwakura et al.,
2010; Lu et al., 2012) resulting in lower circulating levels (Shi-
mada et al., 2003; Silva et al., 2005; de la Cour et al., 2007). Such
a response is in line with the inhibitory effects of somatostatin-
sst2 on the endocrine secretion of other intestinal hormones
(Pederson et al., 1975; Marco et al., 1983; Rokaeus, 1984; Shi-
ratori et al., 1991; Strowski et al., 2000). Likewise, in humans,
peripherally injected somatostatin (Broglio et al., 2002; Norre-
lund et al., 2002) and somatostatin agonists such as octreotide
(Barkan et al., 2003) reduce circulating ghrelin in healthy subjects.
Of relevance, chronic subcutaneous infusion of the sst2/sst3/sst5
agonist octreotide-induced suppression of ghrelin plasma levels
is not subject to rapid desensitization in rats and is likely to be
sst2 mediated based on the prominent sst2 mRNA expression in
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the rat stomach (Silva et al., 2005). Further support for a role
of sst2 came from immunoﬂuorescent double labeling studies
detecting the protein expression of sst2 on ghrelin-producing
X/A-like cells of the rat stomach (Stengel et al., 2011c) and sim-
ilarly on human ghrelin-producing gastric mucosal P/D1 cells
(Fischer et al., 2008). Moreover, the selective peptide sst2 ago-
nist (Table 1) injected intravenously decreased circulating levels
of acyl and desacyl ghrelin with a rapid onset (0.5 h) and a
long duration of action (still visible at 2 h; Stengel et al., 2011c).
Lastly, the selective peptide sst2 antagonist (Table 1) injected intra-
venously prevents the decline in circulating ghrelin induced by the
stimulation of endogenous peripheral somatostatin in rats (Sten-
gel et al., 2011c).
The physiological role of peripheral somatostatin-sst2 signal-
ing in the regulation of ghrelin was investigated under conditions
of stimulation of endogenous gastric somatostatin. Urethane is
well established to stimulate gastric somatostatin mRNA expres-
sion and peptide release in rats (Yang et al., 1990). Under these
conditions, plasma ghrelin levels are decreased and the selective
peptide sst2 antagonist (Table 1) injected intravenously prevents
the decline in circulating ghrelin induced by urethane (Stengel
et al., 2011c). Convergent reports showed that abdominal surgery
induces a rapid and sustained inhibition of circulating levels of
ghrelin in rats (Stengel et al., 2010b, 2011b,c). Likewise, iv injec-
tion of the selective peptide sst2 antagonist (Table 1) blocked the
abdominal surgery-induced decrease of plasma ghrelin at 0.5 h
postsurgery (Stengel et al., 2011c). The peptide is likely to act
through paracrine transmission since somatostatin positiveD cells
directly contact ghrelin immunoreactive X/A-like cells in the rat
stomach (Shimada et al., 2003). Interestingly, following abdomi-
nal surgery, acyl ghrelin was reduced more rapidly compared to
desacyl ghrelin which was associated with a reduction of gastric
as well as plasma concentrations of GOAT (Stengel et al., 2011c).
Since blockade of peripheral sst2 signaling restores circulating
levels of ghrelin (Stengel et al., 2011c), these data collectively sug-
gest that peripheral somatostatin may blunt gastric GOAT mRNA
expression and thereby negatively affect the acylation of ghrelin.
In primary pituitary cell cultures somatostatin was reported to
reduce GOAT mRNA expression and somatostatin knockout mice
showed higher GOAT mRNA expression in the pituitary gland
than the wild type (Gahete et al., 2010b). Based on these ﬁnd-
ings, somatostatin may inﬂuence ghrelin signaling not only via
a direct inhibition of secretion but also by modulating the ghre-
lin activating enzyme GOAT. Further support for a physiological
inhibitory action of peripheral somatostatin on ghrelin signal-
ing came from somatostatin knockout mice that displayed an
increased gastric ghrelin expression and higher circulating ghre-
lin levels compared to their wild type littermates (Luque et al.,
2006a). These data indicate that endogenous somatostatin exerts
a physiological inhibitory tone on gastric ghrelin synthesis and
release.
During the past years, several clinical studies described ghrelin-
producing NETs (Papotti et al., 2001; Volante et al., 2002; Taal
and Visser, 2004) including six insulinomas, gastrinomas, vasoac-
tive intestinal polypeptide (VIP)omas, non-functioning tumors
(Volante et al., 2002) and as part of the multiple endocrine neo-
plasia type 1 (MEN-1; Iwakura et al., 2002; Raffel et al., 2005;
Ekeblad et al., 2007). Moreover, ghrelinomas have been identiﬁed
to originate from the stomach or pancreas and were associated
with very high ghrelin levels (Corbetta et al., 2003; Tsolakis et al.,
2004). Growing evidence from clinical reports indicates that in
addition to the surgical, chemotherapeutic, alpha-interferon, and
local radiation treatments, the use of somatostatin or somatostatin
analog is an established treatment option for gastroenteropancre-
atic NETs (Pavel and Wiedenmann, 2011). Based on the evidence
described above, the determination of the sst subtype expressed
on those ghrelinoma tumor cells followed by the use of periph-
erally acting selective sst compounds may result in an even more
targeted approach.
INTERACTION OF CORTISTATIN WITH GHRELIN
SIGNALING
In 1996, the discovery of a new peptide sharing 11 of its 14
amino acids with somatostatin-14 was named cortistatin based
on its predominant cortical expression and ability to depress cor-
tical activity (de Lecea et al., 1996). Despite the chemical structure
homology with somatostatin, both peptides are derived from dis-
tinct genes (de Lecea et al., 1997b). Similar to pro-somatostatin,
processing of cortistatin precursor generated two mature prod-
ucts, cortistatin-14 and -29 in rodents and cortistatin-17 and -29
in humans (Fukusumi et al., 1997; Spier and de Lecea, 2000).
Cortistatin is widely expressed in the brain, namely in the cor-
tex and hippocampus, and although regional overlap exists, the
distribution pattern differs from that of somatostatin (de Lecea
et al., 1997a). Likewise, the peripheral expression pattern of cortis-
tatin (e.g., in adrenal, thyroid, and parathyroid gland, testis,
pancreas, kidney, lung, liver, stomach, ileum, jejunum, colon,
endothelial, and immune cells) does not fully match that of
somatostatin (Papotti et al., 2003; Dalm et al., 2004; Xidakis et al.,
2007). Consistent with being a close somatostatin endogenous
analog, cortistatin contains the FWKT tetramer crucial for sst
binding, and therefore displays high-afﬁnity (1–2 nM) to all ﬁve
sst subtypes where the peptide acts as an agonist (Fukusumi
et al., 1997; Siehler et al., 2008). However, emerging evidence
indicates that cortistatin induces distinct central and peripheral
effects that differ from those exerted by the somatostatin-sst
interaction such as central acetylcholine release, reduction of loco-
motor activity, depression of cortical activity, induction of slow
wave sleep, anti-inﬂammatory and immunomodulatory effects,
and reduction of vascular calcium deposition (for review, see
Spier and de Lecea, 2000; Broglio et al., 2007; Gonzalez-Rey and
Delgado, 2008).
The existence of a speciﬁc cortistatin receptor has not been
identiﬁed yet but differential actions between somatostatin and
cortistatin may possibly reside in the ability of cortistatin to
bind and to activate the GRLN-R, whereas somatostatin does
not (Deghenghi et al., 2001b; Muccioli et al., 2001). Divergent
from native somatostatin, however, synthetic somatostatin ago-
nists, lanreotide, octreotide, and vapreotide bind to the GRLN-R
in human pituitary tissue (Deghenghi et al., 2001c) in addition
to their selective afﬁnity for sst2 > sst5 > sst3 (Bauer et al., 1982;
Reichlin, 1983; Redding and Schally, 1984). In addition to binding
studies, few functional ﬁndings also support the possibility that
cortistatin may be another endogenous high-afﬁnity ligand of the
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GRLN-R. Cortistatin has been reported to inhibit vascular calci-
ﬁcation induced experimentally in rats through activation of the
GRLN-R receptor rather than sst or Mrg X2 (Liu et al., 2010). Of
interest was the demonstration that cortistatin selectively upreg-
ulates the GRLN-R mRNA expression in cultured rat vascular
smooth muscle cells, further indicative of an interaction between
cortistatin and ghrelin signaling (Liu et al., 2010). Other studies
in primates and mice demonstrated that endogenous cortistatin,
unlike somatostatin, is involved in the stimulation of pituitary
prolactin release, an effect that is blocked in vitro by the GRLN-R
antagonist (Cordoba-Chacon et al., 2011). However, most of the
endocrine studies performed in vivo or in vitro showed parallel
inhibitory responses between cortistatin and somatostatin con-
sistent with the activation of classical sst subtypes (Broglio et al.,
2008) with some exceptions (Prodam et al., 2008). This is further
corroborated by the ﬁnding that cortistatin knockout mice display
elevated circulating acyl ghrelin levels associated with an upregu-
lated gastric ghrelin andGOATexpression (Cordoba-Chacon et al.,
2011) indicating an inhibitory tone of endogenous cortistatin on
ghrelin signaling.
To further delineate the actions of cortistatin mediated via
the GRLN-R another peptide, cortistatin-8, has been shown to
bind to the GRLN-R while being devoid of afﬁnity to the sst
subtypes (Luque et al., 2006b). However, in one clinical study
cortistatin-8 did not inﬂuence spontaneous pituitary hormone
secretion (GH, prolactin, and ACTH) and did not interfere
with ghrelin’s endocrine responses when given in equimolar dose
ratios in healthy human subjects (Prodam et al., 2008). Therefore,
additional speciﬁc tools may be needed to characterize a possible
direct link between the ghrelin and somatostatin signaling system
via interaction on the GRLN-R.
SUMMARY
In summary, somatostatin robustly affects circulating levels of
ghrelin through interaction with the sst2. However, alterations
vary with the site of action. Central somatostatin elevates plasma
levels of acyl and desacyl ghrelin via interactionwith brain sst2 and
counteracts the visceral stress-related decrease in circulating ghre-
lin through pathways still to be elucidated in rodents. By contrast,
the activation of peripheral somatostatin-sst2 inhibits circulating
ghrelin levels in experimental and clinical studies and mediates
the decline in circulating ghrelin induced by abdominal surgery
in rodents likely via a paracrine action of somatostatin on sst2-
bearing ghrelin cells in the stomach. Of interest, cortistatin, the
othermember of the somatostatin family, in addition to binding to
sst1−5, also binds to and activates the GRLN-R. There is evidence
that the peptide can exert a dual inﬂuence on ghrelin, by inhibiting
its release through interaction with sst2 located on gastric ghrelin
cells while activating GRLN-R at ghrelin’s tissue targets.
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